NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Clean Science and Technology Sees Mixed Quarterly Performance, Maintains Growth Momentum

Clean Science and Technology reported revenue of Rs2.5 billion in Q4FY26, marking a decline of 5.5% year-over-year (YoY) but an increase of 13.5% quarter-over-quarter (QoQ). The sequential performance was primarily driven by higher customer offtake and recovery in volumes.

The company's HALS business achieved its highest ever quarterly revenue in Q4FY26, with volumes crossing approximately 1,000 metric tons (mt) during the quarter. Additionally, exit utilization reached 40% in March, supported by an improving product mix and rising exports. The segment also turned EBITDA positive for the first time, reporting a profit of Rs70-80 million during the quarter. Clean Science and Technology expects the growth momentum in HALS to continue, led by higher-grade products.

The company is undertaking backward integration into key HALS intermediates by repurposing the DHTT (pharma intermediate) facility. Furthermore, for the Hydroquinone (HQ) and Catechol plant commissioned in December 2025, management expects a gradual ramp-up over the coming quarters. On the capex front, commercialization of Performance Chemical 2 is now expected by September 2026, delayed due to manpower shortages.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Outlook and Recommendations

Upcoming capacity additions are likely to support growth; however, we remain cautious given macroeconomic volatility and lower realizations in certain legacy products. At the current valuation of 24x FY28E EPS, we maintain a 'HOLD' rating on CLEAN, with a target price (TP) of Rs846, based on 25x FY28 EPS.

| Comparison of Quarterly Performance | | --- | --- | --- | | Q4FY26 | Q4FY25 | Q3FY26 | | Revenue (Rs billion) | 2.5 | 2.65 (YoY decline of 5.5%) | 2.2 (QoQ increase of 13.5%) | | HALS Business Revenue (Rs million) | | | | | Volumes (mt) | 1,000 | | | | Exit Utilization (%) | 40% | | | | EBITDA Profit (Rs million) | 70-80 | | |

Note: All figures are in Indian Rupees (Rs) unless specified otherwise.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Investor Takeaway

Investors should consider holding Clean Science and Technology with a target price of Rs 846.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.